The Covid-19 pandemic panic has receded – at least in the US – into a tactical retreat of common-sense “reopening” protocols for much of the country. That entails increased demands for personal protection equipment and cleansing agents capable of allowing more people to return to a more normal pattern of behavior without sparking an acceleration in new cases.
That process creates an opportunity for potential investors in companies like BioLargo, Inc. (OTCMKTS:BLGO), which is a “solution play” for just such a context.
BioLargo focuses on unique disruptive solutions to deliver clean air, clean water and a clean, safe environment. The company has a deep and expansive R&D facet, with collaborations, including UCLA, Shell Co, Suncor, Total, Epcor, NWRI, EREF, and a substantial list of top north American universities in the US and Canada.
The company’s engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Its industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs.
BLGO’s subsidiary, BioLargo Water (www.biolargowater.ca), develops the Advanced Oxidation System “AOS,” a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies.
And its subsidiary, Clyra Medical (www.clyramedical.com), features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.
BioLargo has a wide array of issued patents, an extensive R&D talent pool, and a full-service engineering team, the company maintains a robust pipeline of products from inception through maturity. The company monetizes its technology assets with the goal of maximizing both impact and shareholder value, using licensing, strategic partnership, and direct-to-market strategies.
How does this play into the reopening theme?
BLGO recently patented its CupriDyne® technology that was proven in a third-party study to be effective in inactivating SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic.
In addition, “Clyraguard” (pronounced “Clear-a-Guard”), which was developed by its partly-owned subsidiary, Clyra Medical Technologies, also just underwent a third-party study at a top national biohazard lab, where it was proven to cause complete inactivation of the SARS-CoV-2 virus in laboratory testing.
Moreover, the product can be sprayed right in your eyes and it wouldn’t hurt you. It can, therefore, be used to clear N95 masks used by front-line health workers to extend their utility.
By any standard, this is a superior technology solution given the current crisis/context. R&D successes are important. But bringing them successfully to market is where the magic generally happens for shareholders.
That’s why we were even more interested when we saw the company’s recent announcement on establishing a new Chief Business Development Officer at Clyra.
John Sirpilla, according to information provided by the company, is the former President of Camping World Accessory Stores, a 140-store nationwide retail chain serving the RV industry. He was promoted in 2012 to Chief Business Development Officer for the parent company, Camping World and Good Sam, with annual sales of nearly $4 billion.
Mr. Sirpilla also sits on the board of trustees of the Pro Football Hall of Fame, Hall of Fame Health, publicly traded LCI, Aultman Health Foundation, and other medical device boards. In other words, he’s a ringer.
BLGO also has a nearly $750K in cash on the books and pulled in revenues of $1.9M over the past year on better than 20% y/y growth.